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Abstract
Electrochemical potential-driven transporters represent a vast array of proteins with varied substrate specificities. While diverse in size and substrate
specificity, they are all driven by electrochemical potentials. Over the past five years there have been increasing numbers of X-ray structures reported for
this family of transporters. Structural information is available for five subfamilies of electrochemical potential-driven transporters. No structural
information exists for the remaining 91 subfamilies. In this review, the various subfamilies of electrochemical potential-driven transporters are discussed.
The seven reported structures for the electrochemical potential-driven transporters and the methods for their crystallization are also presented.With a few
exceptions, overall crystallization trends have been very similar for the transporters despite their differences in substrate specificity and topology. Also
discussed is why the structural studies on these transporterswere successfulwhile others are not as fruitful.With the plethora of transporterswith unknown
structures, this review provides incentive for crystallization of transporters in the remaining subfamilies for which no structural information exists.
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Electrochemical potential-driven transporters, also known as
secondary active transporters, are a diverse class of transporters
that uses an electrochemical gradient to drive transport: the
transport of a substrate uphill against its concentration gradient, a
thermodynamically unfavorable scenario, is driven by the
transport of another substrate down its concentration gradient.
Besides electrochemical potential-driven transporters, other
classes of transport proteins exist that use different types of
energy to drive transport, including channels, ATP-driven (also
known as primary active) transporters, group translocator
transport and transport electron carriers for a total of over 360
families (for a complete list of transporters and families see http://
www.tcdb.org/index.php).
Electrochemical potential-driven transporters can be divided
into three sub-classes: 1) porters (uniporters, symporters, anti-
porters), 2) non-ribosomally synthesized porters, and 3) ion-
gradient-driven energizers. There are an astounding 88 sub-
families within the porters sub-class, seven subfamilies in the
non-ribosomally synthesized porters, and one family of trans-
porters in the ion-gradient-driven energizers sub-class. This adds
up to 96 subfamilies for electrochemical potential-driven trans-
porters. Given this large number, there are few, although
increasing, X-ray structures representing electrochemical poten-
tial-driven transporters.
Thus far structural information exists for seven transport-
ers in the porter sub-family. For an up-to-date list on struc-
tural progress of membrane proteins, see http://blanco.biomol.
uci.edu/Membrane_Proteins_xtal.html. This review will sum-
marize the structural information available for inner membrane
gradient-driven transporters. The structures will be reviewed as
well as their method for crystallization. In addition, the future for
inner membrane transporter structural studies will be discussed.
2. Structural studies of porters: antiporters, symporters
and uniporters
2.1. Structure and crystallization of the Major Facilitator
Superfamily
2.1.1. The glycerol-3-phosphate transporter, GlpT
E. coli GlpT is an antiporter exchanging glycerol-3-phosphate
(G3P) for inorganic phosphate. Most biochemical studies with
GlpT involved characterization of its transport function in the
inner membrane of E. coli including the identification of the
transporter separate from the Pst and Pit phosphate transport
systems [1]. Reconstitution of the GlpT protein demonstrated that
phosphate efflux is not only elicited by G3P but also by inorganic
phosphate [2]. Although its exact role in E. coli is yet to bedetermined, GlpT may play a role in either glycolysis and/or
phospholipid metabolism [3]. As predicted by hydropathy
analysis [4], the crystal structure of GlpT revealed 12 transmem-
brane segments (TMS)with very short N- andC-terminal domains
(Fig. 1A) [5]. The overall architecture ofGlpTconsists of two 6-α-
helical bundles that surround a central cavity responsible for
substrate recognition and passage. The two helical bundles are
connected by a long extramembranous loop that is believed to play
a role in a major conformation transition that accompanies
transport of substrates. GlpTwas crystallized in the inward-facing
conformation. An alternating-accessmechanism for proton-driven
transport was proposed from the structural information.
Crystallization ofE. coliGlpTwas achieved byover-expression
inE. coli of the full lengthwild-typeGlpT (aa. 2–452)with a hexa-
His-tag at the C-terminus in an arabinose-inducible expression
vector (Table 1) [6]. GlpTwas purified in the detergent n-dodecyl-
β-D-maltoside (DDM) using batch Ni-NTA affinity chromatogra-
phy followed by His-tag removal and size exclusion chromato-
graphy (SEC). The detergent C12E9 was added to the purified
protein prior to crystallization, and the best crystals were obtained
in a mixture of DDM and C12E9. Crystallization was carried out
using hanging drop vapour diffusion methods at 18–20 °C with
PEG as the precipitant (See Table 1). Phasing was obtained using a
heavy metal derivative, Na9(P2Nb3W15O62).nH2O, which was
soaked into the crystals. Selenomethionine-substituted GlpT was
also generated but the electron difference data was used only in the
tracing of the electron density.
2.1.2. Lactose permease, LacY
LacY of E. coli is a symporter that transports galactoside
against its gradient by coupling with the downhill transport of a
proton, thereby playing a role in carbohydrate metabolism in
E. coli. Being one of the most well-characterized transporters,
ample biochemical studies have been carried out on LacY,
including site-directed mutagenesis and cysteine-scanning muta-
genesis of every amino acid [7]. The structure of LacY revealed
12-TMs (Fig. 1B) [8]. The overall architecture is similar to the
structure of GlpT with two 6-α-helical bundles separating a
central cavity responsible for substrate transport. As with the
GlpT transporter, LacY was also crystallized in the inward-facing
conformation. Crystals were obtained of both native and
substrate-bound LacY (lactose analog, β-D-galactopyranosy-1-
thio-B-D-galactospyranoside or TDG). No structural differences
were observed between the two states. More recently, another
structure of LacY was reported at two different pH levels of 5.6
and 6.5 respectively, at higher resolution, 3.30 Å and 2.95 Å,
compared to the initial structure [9]. These structures were
determined in the absence of bound substrate TDG. The overall
structure is similar to the initially reported structure, RMSD of
1.0Å, with the exception of side chain residues. This structure has
Fig. 1. Ribbon representation of the X-ray structures for electrochemical potential-driven transporters. The pdb codes and references are given for the transporters
represented. A. GlpT, IPW4.pdb [5]; B. LacY, 1PV7.pdb [8]; C, EmrD, 2GFP.pdb [12]; D. AcrB, 2DHH.pdb [15]; E. LeuT, 2A65.pdb [18]; F. GltAa, 1XFH.pdb [24];
G. NhaA, 1ZCD.pdb [30].
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alternating-access model of proton-driven transport.
Crystallization of LacYwas carried out by over-expression of a
deca-His-tagged LacY with a C154G mutation, one which binds
substrate with high affinity, catalyzes little or no transport, and is
thermostable, in an IPTG inducible vector (Table 1) [10]. LacY
was solubilized with DDM and purified via Talon resin affinity
column. Hanging drop vapour diffusion methods at 20 °C with
PEG as the precipitant were used to generate crystals (see Table 1).
Prior to crystallization, the sample was pre-incubated with
methylmercuric acetate (MMA, 3-fold molar excess over protein)
for 3 h at 20 °C. The subsequent structures of LacYwere generated
as above except that the detergent:protein ratio for solubilization
step was modified by increasing it to 2.5:1.0 (wt/wt; 10 mg
protein/ml) [9]. Crystallization was carried out at 5.6 for the acidic
pH. These crystals were then soaked at pH 6.5 for 2 min prior to
cooling for data collection in order to generate the higher pH
crystals of LacY.2.1.3. Multidrug transporter EmrD
E. coli EmrD is a proton dependent multidrug antiporter. This
MFS transporter is unique compared to GlpTand LacY in that it is
less specific in its substrate specificity, transporting a diverse
number of hydrophobic molecules such as the mitochondrial
uncouplers carbonyl cyanide m-chlorophenylhydrazone (CCCP)
and benzalkonium, as well as detergents, SDS for example [4].
EmrD is thought to play a role in a low energy shock adaptive
response as its expression is increased in the presence of un-
couplers [11]. The crystal structure of EmrD revealed 12-TM
segments (Fig. 1C) with a similar organization to LacYand GlpT
[12]. A hydrophobic interior, consisting of mostly aromatic res-
idues, provides the means for the transport of hydrophobic
compounds byEmrD. This is in contrast to the hydrophilic interior
found with both GlpT and LacY. Another difference between the
structures is the two extended segments, loop 4–5 and loop10–11,
located on the cytoplasmic face of EmrD, which are proposed to
provide additional substrate recognition.
Table 1
Overview of methods for crystallization of the electrochemically driven transporter sub-classes structures to date
Transporter [ref] year Res (Å) Expression vector/strain Detergent(s) Reservoir conditions for crystallization Phasing
2. Porters
2.1. Major facilitator superfamily transporters
GlpT [5] 2003 3.3 pBAD-MycHisA
(Invitrogen) in
E. Coli
Top10 cells
0.15–0.23%
n-dodecyl-β-maltoside
and 0.06–0.09% C12E9
25% to 27% PEG 2000MME,
0.1 M Tris (pH 8.5 to 8.9),
20% glycerol, 5% MPD,
5 to 100 mM NaCl, and
5 mM SrCl2 or MgCl2,
grown at 15 °C to 20 °C
SIRAS with W cluster
(Na9(P2Nb3W15O62).
nH2O) and SeMet
LacY [8] 2003 3.5 T7 promoter in
E. coli XL1-Blue
(Stratagene)
n-dodecyl-β-maltoside
and CHAPS
100 mM HEPES
(pH 7.0)/27–30%
PEG 400/200 mM
CaCl2/3% 1,6-hexanediol/
0.8 mM CHAPS at 20 °C
MAD with
covalently-bound Hg
EmrD [12] 2006 3.5 pET19 vector
(Novagen) in
E. coli
BL21 cells
n-dodecyl-β-maltoside 18–25% PEG 400, 50–100 mM
sodium citrate pH 3.8–5.2,
25-100 mM KCl at 22 °C
2 wavelength MAD,
peak and inflection,
using gold thiomalate
soaked crystals
2.2. Resistance-Nodulation-Cell Division (RND) superfamily
AcrB [13] 2002 3.5 JM109 cells n-dodecyl-β-maltoside 15–16% polyethylene
glycol 2000, 80 mM sodium
phosphate (pH 6.2), 20 mM
sodium citrate–HCl (pH 5.6)
MIR with 0.5 mM
K2HgI4, 1 mM K2PtCl6
and 1 mM OsCl3,
plus SeMet
AcrB [14] 2003 3.7 pUC151A plasmid
in DH5 cells
n-dodecyl-β-maltoside 7% polyethylene glycol 4000,
20–40 mM sodium (or
potassium) citrate, pH 5.6 or
6.5, and in some cases 20–50
mM KNO3 and 10% glycerol
MR
AcrB [15] 2006 2.9 JM109 cells n-dodecyl-β-maltoside 14% (w/v) polyethylene glycol
4000, 100 mM sodium phosphate
(pH 6.2), 50 mM NaCl
MR and MIR with
0.5 mM mercuric
potassium iodide,
1 mM trimethyl
lead acetate, and
1 mM potassium
tetrachloroplatinate
and SeMet
substituted AcrB
to improve phases
AcrB [16] 2006 2.9 NR n-dodecyl-β-maltoside 5% polyethylene glycol 400,
16–22% polyethylene glycol
300, 8–11% glycerol and
70 mM Na+-citrate pH 4.6
MR
2.3. Neurotransmitter:Sodium Symporter (NSS) family
LeuTAa [18] 2005 1.65 pET16b in C41 cells n-dodecyl-β-maltoside/
n-octyl-β-D-glucopyranoside
0.1 M HEPES-NaOH (pH 7.0),
18–22% PEG 550 MME,
and 0.2 M NaCl
3 λ MAD with
selenomethionine
LeuT-Clo⁎ [19] 2007 1.85 pET16b in C41 cells n-dodecyl-β-maltoside/
n-octyl-β-D-glucopyranoside
17–22% PEG 550 MME,
100 mM HEPES-NaOH
(pH 7–7.5) and 200 mM NaCl
MR
LeuT-Des [20] 2007 2.9 pBAD in
BL21-pLysS cells
n-dodecyl-β-maltoside/
n-octyl-β-D-glucopyranoside
0.1 M HEPES-NaOH
(pH 6.8), 18% PEG 550
MME and 0.2 M NaCl
MR
2.4. Dicarboxylate/Amino Acid:Cation (Na+ or H+) Symporter (DAACS) family
GltPh [23] 2004 3.5 pBAD24 in
Top10 cells
n-dodecyl-β-maltoside 14–18% PEG 1000,
100 mM Li2SO4, 50 mM
citric acid, 50 mM Na2HPO4
MAD with 50 mM
K2Pt(NO2)4
GltPh-Asp⁎ [25] 2007 2.96 pBAD24 in
Top10 cells
n-dodecyl-β-maltoside 14–18% PEG 1000, 100 mM
Li2SO4, 50 mM citric acid,
50 mM Na2HPO4 plus L-Asp
MR
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2.5. The NhaA Na+:H+ Antiporter (NhaA) family
NhaA [30] 2005 3.8 pAXH plasmid
in RK20 cells
n-dodecyl-β-maltoside 28–34% v/v polyethylene
glycol 400, 200–450 mM
MgCl2, 100 mM KCl, 25 mM
sodium citrate pH4, 1%
n-octyl-b-D-glucopyranoside
and 0.5% ethanol
SAD with SeMet
substituted NhaA
3. Non-ribosomally synthesized porters
None reported to date
4. Ion-gradient-driven energizers sub-family
4.1. The TonB–ExbB–ExbD/TolA–TolQ–TolR (TonB) family of auxiliary proteins for energization of Outer Membrane Receptor (OMR)-mediated active transport
None reported. Thus far, only the C-terminal domain of the soluble TonB peptide of the TonB–ExbB–ExbD transporter has been solved in complex with BtuB and
with FhuA
Res: resolution, NR: not reported, SIRAS: single isomorphous replacement with anomalous signal, MR: molecular replacement; MAD: multiple anomalous
dispersion, SAD: single anomalous dispersion. ⁎Note: the crystallization condition is only given for one complex.
Table 1 (continued)
1809M.J. Lemieux / Biochimica et Biophysica Acta 1778 (2008) 1805–1813Crystallization of EmrD was carried out by the expression of
a deca-His-tagged protein with an IPTG inducible vector in
BL21 E. coli and purification using Ni-NTA metal affinity
column (Table 1) [12]. DDM was used to extract the protein
from the cells prior to purification. Crystals were grown using
the sitting drop technique at 22 °C using PEG as the precipitant.
Phasing was determined by 2 wavelength MAD experiment
using gold thiomalate which was soaked into EmrD crystals.
2.2. Structure and crystallization of the
Resistance-Nodulation-Cell Division (RND) superfamily
2.2.1. Multidrug transporter AcrB
Multidrug resistance is found ubiquitously in all living
organisms. This is important for survival because organisms are
constantly bombarded with various environmental chemicals, it
is problematic for drug therapies. The primary multidrug tran-
sporter in E. coli is AcrB. The first structural studies carried out
on AcrB revealed a trimeric protein that consisted of three
individual AcrB protomers (Fig. 1D) [13]. Together the trimer
forms three separate domains: a TolC docking domain located
in the periplasmic space, a porter domain that interacts with the
soluble AcrA protein bridging AcrB to TolC, and lastly a
transmembrane domain. The following year, a second group
presented the structure of AcrB in complex with four different
ligands [14]. Each ligand was identified at a unique site within
the central cavity of the trimer. While the initial structures of
AcrB showed symmetry in the molecule, two structures of AcrB
published in 2006 show deviations from this symmetry [15, 16].
In the latest reported structures, each AcrB molecule in the
trimer is present in a different conformation. This asymmetry
has provided new insight into the mechanism by which these
transporters are able to extrude molecules from the cytoplasm
and periplasmic space and have led the authors to present a
functionally rotating mechanism for transport [15,16].
Crystallization of the initial structure of AcrB involved over-
expression of a His-tagged protein using an IPTG inducible
vector in JM109 cells (Table 1) [13]. Membrane proteins were
extracted using DDM. AcrB was purified using ChelatingSepharose. For protein substituted with seleno-1-methionine,
AcrB was expressed in E. coli B834 (DE3) cells. Crystals were
grown by vapour diffusion from sitting drops at 25 °C. Phasing
was carried out using multiple isomorphous replacement while
the selenomethionine-substituted AcrB difference map was
used in the fitting of the electron density map. Preparation and
crystallization conditions of AcrB from the Koshland et al. [14]
are different from that reported for the initial structure (Table 1).
The wild-type AcrB was overproduced in E. coli DH5 cells
containing the plasmid pUC151A. The purified membrane pro-
tein was solubilized in DDM (w/v) and purified with hydro-
xyapatite, Cu2+-affinity and G-200 sizing columns. All crystals
were grown by sitting drop vapour diffusion at 25 °C using PEG
as the precipitant. Yamaguchi et al. second report of the AcrB
structure was modified from their initial crystallization that
resulted in a different space group, C2 [15] from the original R32
(Table 1). PurifiedAcrBwas prepared as previously reported [13].
Drug complexes were prepared by adding 2.4 mM minocycline,
1.2 mM doxorubicin or 12 mM 9-bromo-minocycline to the
purified protein with incubation overnight at 4 °C. Crystals were
grown by the vapour diffusion method from hanging drops at
20 °C as opposed to the sitting drop method as with their initial
crystallization conditions. The fourth report of AcrB structure,
from Pos et al., revealed crystals belonging to monoclinic (C2,
2.9 Å resolution) and triclinic (P1,3.0 Å resolution) space groups
[16]. Membrane proteins were solubilized from the lipid bilayer
using DDM. Prior to crystallization, ethidium or dequalinium was
added (400 μM or 200 μM final concentration, respectively). It
was reported that the addition of the drug was beneficial in
obtaining high quality crystals. Crystals were grown by hanging
drop vapour diffusion at 17 °C.
2.3. Structure and crystallization of the Neurotransmitter:Sodium
Symporter (NSS) family
2.3.1. Leucine transporter, LeuT
LeuTAa, a leucine transporter from the bacterium Aquifex
aeolicus, is a symporter which uses a Na+/Cl− gradients to drive
leucine transport. The exact stoichiometry for transport can vary
1810 M.J. Lemieux / Biochimica et Biophysica Acta 1778 (2008) 1805–1813from 1:1:1, 2:1:1 or 3:1:1 Na:Cl:substrate. In higher organisms,
this transporter is responsible for the removal of the amino acid
neurotransmitter from the synaptic cleft. The clearance of
leucine from the cleft is required before another depolarization
cycle can occur. Depression, Parkinson's disease, orthostatic
intolerance and epilepsy are but a few of the disorders attributed
to the dysfunction of Na+/Cl− transporters in humans [17].
Addictive substances such as cocaine and amphetamine, as well
as therapeutic agents such as anticonvulsants and the selective
serotonergic re-uptake inhibitors are targets of this transporter
family. Three structures are currently available for LeuT from
A. aeolicus [18–20]. The initial structure of LeuTAa, published
in 2005 by the Gouaux et al., was solved at a very high
resolution for a membrane protein, 1.65 Å, allowing a detailed
view of the substrate binding region of the protein (Fig. 1E)
[18]. The transporter exists as a dimer with each protomer con-
sisting of 12-transmembrane segments arranged in “shot glass”
architecture. Within each protomer, electron density for a leucine
molecule and two sodium ions were visible. One of the sodium
ions interacts with the leucine bound in the substrate pocket. The
second structure from Gouaux's group revealed the structure of
LeuTAa in complex with non-competitive inhibitors, clomipra-
mine, desipramine or imipramine as well as the alanine- and
sodium-bound state of LeuT in complex with clomipramine. All
inhibitors bound in the putative permeation pathway at an
extracellular-facing vestibule about 11Å above the substrate, with
two sodium ions cradled by an extracellular loop, EL4. Confor-
mational changes were observed in EL4 upon substrate binding
revealing its role in tricyclic antidepressant inhibition. This inhi-
bition resulted in a closed conformation of the gate trapping the
substrate in LeuTAa. The third structure of LeuTAa, from the group
of Wang, revealed a co-crystal structure with a different TCA,
namely desipramine [20]. This molecule was also found in the
vestibule above the extracellular gate in LeuT. The leucine andNa+
ions did not change position compared to the uninhibited structure.
Crystallization of LeuTAa involved over-expression of an
octa-His-tagged protein in an IPTG inducible vector in C41
cells, a strain of E. coli that has been optimized to produce large
quantities of membrane proteins (Table 1) [21]. Membrane
fractions were collected and proteins extracted with DDM.
Purification was carried out on a metal affinity column. Post-tag
removal, the protein was subjected to detergent exchange into
n-octyl-β-D-glucopyranoside on a size exclusion column. Cry-
stallization was carried out using hanging drop vapour diffusion
at 18 °C. Phasing was determined using selenomethionine-
substituted LeuTAa in a 3 wavelength MAD experiment. For
crystallization with the TCA, protein was incubated with the
compounds for 15 min prior to crystallization at 4 °C [19]. For
the LeuT-desipramine structure, the protein was over-expressed
as a hexa-His-tagged protein using an arabinose-inducible
vector in BL21-pLysS cells [20]. Membrane fractions were
isolated and solubilized with DDM and purified with Ni-NTA
resin. Using a size exchange column the protein was subjected
to detergent exchange into n-octyl-β-D-glucopyranoside. Crys-
tallization was carried out using hanging drop vapour diffusion
with PEG as the precipitant at 20 °C. Phases were calculated
using molecular replacement.2.4. Structure and crystallization of the Dicarboxylate/Amino
Acid:Cation (Na+ or H+) Symporter (DAACS) family
2.4.1. Glutamate transporter, GltPh
GltPh, a sodium dependent glutamate/aspartate symporter
from Pyrococcus horikoshii, is an ancestor to the human gluta-
mate transporter. The human counterpart is responsible for the
uptake of the excitatory neurotransmitter glutamate at synaptic
clefts post depolarization and neurotransmitter release (for
review, see [22]). As with the leucine transporter, the clearance
of glutamate from the cleft is essential to provide an opportunity
for another depolarization cycle. The glutamatergic synapse is
integral for learning and memory. The topology of the glutamate
transporters has been studied extensively and remained con-
troversial until the elucidation of the structure in 2004 [23]. The
structure of GltPh revealed a trimer with a central cavity in the
shape of a “bowl” Fig. 1F [24]. Each GltPh protomer consists of
8 transmembrane segments with 2 re-entrant hairpin loops that
enter the lipid bilayer without spanning it completely. The
hairpins flank the three substrate binding regions found within
each protomer. Glutamate was included in all purification steps
for crystallization, yet at the resolution of 3.5 Å, it could not be
modeled with certainty. The second group of GltPh structures
was published in 2007 in complex with aspartate and a non-
transportable blocker [25]. GltPh preferentially transports aspar-
tate over glutamate. Aspartate was identified between the two
hairpins in each protomer. Co-crystallization with a non-trans-
portable substrate D,L-threo-b-benzyloxyaspartate (TBOA) was
also carried out. These structures revealed that hairpin2 (HP2),
acting as a gate, undergoes considerable conformational change
which in turn allows the opening of an internal gate to the central
bowl. Thallium was used to identify the two sodium binding
sites, one of which is associated with aspartate and the other with
HP2.
Crystallization of GltPh involved expression of an octa-His-
tagged protein in Top10 cells using an arabinose-inducible
promoter (Table 1) [23]. Crude membrane fractions were isolated
andmembrane proteins solubilizedwithDDM.GltPh was purified
using Ni-NTA resin. Crystallization was carried out at 4 °C using
hanging drop vapour diffusion [24]. Phases were determined to
8 Å using MAD data from a platinum derivate. Phases were then
extended to 3.5 Å using three-fold averaging, solvent flattening
and histogram matching with the program Density Modification.
In addition, a selenomethionine difference map was used to
facilitate model tracing. Crystallization of GltPh in complex with
L-aspartate and TBAO was carried out in a similar fashion as
above except substrates L-Glu, L-Asp or D-Asp were included in
the expression, purification and crystallization stages [25]. In
some cases before crystallization the protein solution was
supplemented with E. coli total lipid extract.
2.5. Structure and crystallization of the NhaA Na+:H+
Antiporter (NhaA) Family
2.5.1. Sodium-proton antiporter, NhaA
NhaA is a Na/H+ antiporter from E. coli responsible for
regulating the intracellular pH,Na+ concentration and volumeof a
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terpart, NHE1, has also been studied extensively and its activity
has been shown to play a role in cell differentiation, apoptosis,
cytoskeleton organization and pH regulation in myocardial cells
(for review see [26]). NHE1 has been linked to heart disease by its
role in myocardial acid control [27]. During myocardial ischemia
and reperfusion, NHE1 activity is linked to damage [28]. In ad-
dition, Na/H+ antiporters have been shown to contribute to
cardiac hypertrophy [29]. NHE1's role in establishing an alkaline
cell and its role in the activation of a number or mitogenic factors
implicate NHE1 in tumorigenicity [26]. The structure of NhaA
revealed 12 transmembrane segments (Fig. 1G) [30]. There are
two individual domains present in the structure: one consists of
two three-helical bundles while the other is a six-helical bundle.
At the center of the two domains is a cavity that is open to the
cytoplasm.
Crystallization of NhaAwas carried by the over-expression of
a His-tagged protein using an IPTG inducible vector with RK20
cells (Table 1) [30]. Membrane proteins were solubilized from the
membrane using DDM and NhaAwas purified using Ni-affinity
column where the detergent was exchanged to n-dodecyl-α-D-
maltopyranoside. Crystals were grown at 6 °C by hanging
drop vapour diffusion using PEG as the precipitant. In addition
selenomethionine-substituted NhaA was generated as described
above except using the E. coli B834DE3 strain. These crystals
were used for SAD phasing.
3. Structural studies of the non-ribosomally synthesized
porters
Seven families are present in this class of transporters, however,
no structures reported at present.
4. Structural studies of the ion-gradient-driven
energizers sub-family
4.1. Structure and crystallization of the TonB–ExbB–ExbD/
TolA–TolQ–TolR (TonB) family of auxiliary proteins for
energization of Outer Membrane Receptor (OMR)-mediated
active transport
4.1.1. Ton B
Only one family is found in this sub-class of electrochemical
potential-driven transporters. Thus far, only the C-terminal do-
main of the soluble TonB peptide of the TonB–ExbB–ExbD
transporter has been solved in complex with the outer membrane
receptors BtuB [31] and with FhuA [32]. Although these were
both complicated structures to complete, since the membrane
electrochemical potential-driven component was not solved fully,
the structures will not be presented here.
5. Lessons from the structural studies of electrochemical
potential-driven transporters
The structures of seven electrochemical potential-driven trans-
porters have been presented, not counting the duplicate structures.
All structures represented belong to the porter sub-class of trans-porters. Three of these structures are found in the largest family of
transporters in this sub-class, the major facilitator superfamily
(MFS). Considering its size and diversity, it is not surprising that
the majority of the structures exist for this superfamily. The re-
maining structures represent an individual structure for four more
families in the porter sub-class of transporters— the Resistance-
Nodulation-Cell Division (RND) superfamily, the Neurotransmit-
ter:Sodium Symporter (NSS) family, the Dicarboxylate/Amino
Acid:Cation (Na+ or H+) Symporter (DAACS) family, and the
NhaA Na+:H+ Antiporter (NhaA) family.
For the majority of the transporters studied, simple, well-
established methods of purification, detergent-selection, and crys-
tallization proved successful. This seems counterintuitive, since
the structure determination of a transport protein appears to be
such a daunting task. It is reasonable to envisionmore complicated
purification and crystallization schemes are required to solve a
structure of a membrane protein. We see however that purification
obtained by immobilized metal affinity and size exclusion chro-
matographies in the majority of cases was sufficient for crystal-
lization, a strategy similar to standard protein purification
techniques for soluble proteins. Detergent selection relied almost
exclusively on the use of DDM, though several transporters
required additional detergents as additives. For crystallization,
vapour diffusion methods combined with PEGs as precipitants
proved to be a simple but effective approach. No clear trends were
reflected for the phasing methods. Standard anomalous dispersion
techniques, MAD and SAD, as well as isomorphous techniques,
MIR and SIRAS were used. Both LeuT and NhaA used
selenomethionine-substituted protein in crystallization to calculate
phases. Data from selenomethionine-substituted protein crystals
were also used to facilitate tracing with GlpT and AcrB.
Moreover, the commonalities in purification and crystal-
lization are even more unexpected considering the diversity of
membrane topology and domain architecture of the transporters
(Fig. 1). A large extramembranous domain is thought to be
favorable for crystallization, where the hydrophilic surfaces
promote crystal contacts [33]. The gradient-driven transporters,
with the exception of AcrB, aremostlymembrane embeddedwith
loops and helical regions extending into the extramembrane
environment. Indeed crystal contact can be made via these
extramembranous regions as well as via the membrane domains.
With the exception of LeuT, which was solved at 1.65 Å, the
resolution for the transporter structures was moderate, ranging
from 2.9 Å to 3.8 Å. This is a testament to the difficulty in their
crystallization. This is not surprising as gradient-driven transpor-
ters are thought to exist in multiple conformations making
packing of well-ordered crystals more difficult. So why did LeuT
crystals diffract to higher resolution? Perhaps this is attributed to
the inherent stability of this protein from A. aeolicus.
The most striking feature of all of the structures presented is
that they are all derived from bacterial sources. In fact there are
few membrane protein structures from over-expressed eukaryotic
proteins. Prokaryotic proteins tend to over-express to higher
levels compared to their eukaryotic counterparts yielding suf-
ficient protein for structural studies. Therefore to gain insight into
a eukaryotic transporter, one may attempt to crystallize a pro-
karyotic homolog or alternatively one may attempt to persevere
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Structures of eukaryotic membrane proteins do exist for those that
express naturally to a high level, Ca+2 ATPase is a clear example
[34]. However, there are contrary examples of naturally abundant
transport proteins whose structures remain illusive. The erythro-
cyte anion exchanger, also known as Band 3, is naturally abun-
dant and an easily purified transporter. Crystals of this protein
have been generated, but microheterogeneity in the protein
limited the formation of well-ordered crystals [35]. Glut1 is a
well-studied glucose transporter abundant in erythrocytes, yet to
date no report exists of its crystallization. Various models for this
and other transporters for which structural information is not
available have been proposed [36]. Over-expression of eukaryotic
membrane protein to sufficient yield for structural studies has
remained difficult. Nevertheless, in 2005 the group of MacK-
innon solved the structure of the rat voltage-gated potassium
(Shaker family) channel after over-expressing the protein in the
yeast expression system Pichea pastoris [37].
Given the trends seen thus far for crystallization of
electrochemical potential-driven transporters, simple straight-
forward strategies can be employed towards crystallization of
the remaining electrochemical potential-driven transporters:
affinity tag protein purification, the most common being a poly-
His-tag, followed by size exclusion chromatography. Crystal-
lization screens can be streamlined by using PEGs as the
primary precipitants. This is not a unique approach and many
membrane protein crystallographers have adopted this strategy.
Examination of the conditions for the crystallization of the
electrochemical potential-driven transporters solidifies this
general method for streamlining what is a large research
endeavor. This does not imply that solving a structure of a
membrane protein will be easy with this knowledge. There are
other difficulties to overcome besides the actual crystallization,
such as obtaining sufficient yield for structural studies and mod-
ifying the protein such that it is amenable to crystallization. In fact,
the consensus experience is that a well-expressing protein is a
promising first step towards crystallogenesis. Attaining crystals of
GlpTwas never a problem. Simple PEG-based screens yielded too
many crystals to follow up on easily. The challenge was to focus on
a few conditions and to alter the protein so that well-diffracting
crystals were obtained [6]. In fact, phasing was the most difficult
step in solving the X-ray structure of GlpT.
6. Perseverance, intelligent design or luck?
Given the vast array of electrochemical potential-driven trans-
porters characterized, why did the ones presented in this review
yield structures? Was it perseverance, intelligent design or sheer
luck? Maybe a combination of all factors is important?
A good example of perseverance is the case with LacY. The
structure and function of LacY had been studied by Kaback et al.
for over 20 years before yielding a structure [7]. A brute force
scanning-mutagenesis of the entire polypeptide in combination
with biophysical studies ultimately led to a molecular model of
LacY [38]. While some success had been made in the two-
dimensional crystallization of LacY for electron microscopy, no
high resolution structure was forthcoming [39]. In the end, amutation was discovered that locks the protein in the inward-facing
conformation, making the protein suitable for crystallization. This
is a fine example of a brute force approach to the structure and
function of a favorite transport protein. In Kaback's case, the fairy
tale of LacY had a happy ending.
Another common approach to elucidate structures of a protein
with a specific function is to screen homologs of your protein of
interest. This approach proved successful with the MscL channel
[40]. For the GlpT structure, since the Wang lab had a general
interest in sugar transporters, we selected a variety of sugar
transporter homologs that might yield crystals. GlpT, though a
relatively obscure transport protein, was amongst this group of
homologs. All were subjected to expression screening as the next
step in the selection process. Well-diffracting GlpT crystals were
only obtained post-removal of a flexible region at the C-terminus
demonstrating that intelligent design was integral to its success.
With all of the decisions to be made when attempting to solve a
structure – which protein to choose, how to over-express your
protein of interest, how to purify your protein, how to crystallize it–
one must recognize that there are many stages at which the process
may fail. The structure of GlpT is a fine example of a rational
selection process and intelligent design as well as pure good luck.
There are a large number of electrochemical potential-driven
transporters for which no structural information exists, especially
in the porter family where 81 subfamilies remain structurally
uncharacterized. Despite the difficulties, it is the protein that mat-
ters. If you cannot get crystals, or the crystals obtained do not
diffract, change the protein. This can be done by stabilizing a par-
ticular conformation of the protein (inhibitors, substrates, or mu-
tants), changing the domain architecture of the protein (proteolytic
cleavage or genetic manipulation), or changing the entire protein
(homologs). The successful examples discussed herein had an
equal measure of perseverance, intelligent design and good luck.
Acknowledgements
I would like to thank Dr. H.S. Young for his critical reading
of the manuscript. M.J. Lemieux is supported by fellowship
scholarships from CHIR, CIHR strategic training program for
membrane proteins and cardiovascular disease, and Alberta
Heritage Foundation for Medical Research.References[1] C.M. Elvin, C.M. Hardy, H. Rosenberg, Pi exchange mediated by the
GlpT-dependent sn-glycerol-3-phosphate transport system in Escherichia
coli, J. Bacteriol. 161 (1985) 1054–1058.
[2] S.V. Ambudkar, T.J. Larson, P.C. Maloney, Reconstitution of sugar
phosphate transport systems of Escherichia coli, J. Biol. Chem. 261 (1986)
9083–9086.
[3] M.J. Lemieux, Y. Huang, D.N. Wang, Glycerol-3-phosphate transporter of
Escherichia coli: structure, function and regulation, Res. Microbiol. 155
(2004) 623–629.
[4] S.S. Pao, I.T. Paulsen, M.H. Saier Jr., Major facilitator superfamily,
Microbiol. Mol. Biol. Rev. 62 (1998) 1–34.
[5] Y. Huang, M.J. Lemieux, J. Song, M. Auer, D.N. Wang, Structure and
mechanism of the glycerol-3-phosphate transporter from Escherichia coli,
Science 301 (2003) 616–620.
1813M.J. Lemieux / Biochimica et Biophysica Acta 1778 (2008) 1805–1813[6] M.J. Lemieux, J. Song,M.J. Kim,Y. Huang, A. Villa,M.Auer, X.D. Li, D.N.
Wang, Three-dimensional crystallization of the Escherichia coli glycerol-3-
phosphate transporter: a member of the major facilitator superfamily, Protein
Sci. 12 (2003) 2748–2756.
[7] H.R. Kaback, M. Sahin-Toth, A.B. Weinglass, The kamikaze approach to
membrane transport, Nat. Rev., Mol. Cell Biol. 2 (2001) 610–620.
[8] J. Abramson, I. Smirnova, V. Kasho, G. Verner, H.R. Kaback, S. Iwata,
Structure and mechanism of the lactose permease of Escherichia coli,
Science 301 (2003) 610–615.
[9] O. Mirza, L. Guan, G. Verner, S. Iwata, H.R. Kaback, Structural evidence
for induced fit and a mechanism for sugar/H+ symport in LacY, Embo J. 25
(2006) 1177–1183.
[10] I.N. Smirnova, H.R. Kaback, A mutation in the lactose permease of
Escherichia coli that decreases conformational flexibility and increases
protein stability, Biochemistry 42 (2003) 3025–3031.
[11] V. Naroditskaya, M.J. Schlosser, N.Y. Fang, K. Lewis, An E. coli gene
emrD is involved in adaptation to low energy shock, Biochem. Biophys.
Res. Commun. 196 (1993) 803–809.
[12] Y. Yin, X. He, P. Szewczyk, T. Nguyen, G. Chang, Structure of the multidrug
transporter EmrD from Escherichia coli, Science 312 (2006) 741–744.
[13] S. Murakami, R. Nakashima, E. Yamashita, A. Yamaguchi, Crystal
structure of bacterial multidrug efflux transporter AcrB, Nature 419
(2002) 587–593.
[14] E.W. Yu, G. McDermott, H.I. Zgurskaya, H. Nikaido, D.E. Koshland Jr.,
Structural basis of multiple drug-binding capacity of the AcrB multidrug
efflux pump, Science 300 (2003) 976–980.
[15] S. Murakami, R. Nakashima, E. Yamashita, T. Matsumoto, A. Yamaguchi,
Crystal structures of a multidrug transporter reveal a functionally rotating
mechanism, Nature 443 (2006) 173–179.
[16] M.A. Seeger, A. Schiefner, T. Eicher, F. Verrey, K. Diederichs, K.M. Pos,
Structural asymmetry of AcrB trimer suggests a peristaltic pumpmechanism,
Science 313 (2006) 1295–1298.
[17] M.K. Hahn, R.D. Blakely, Monoamine transporter gene structure and
polymorphisms in relation to psychiatric and other complex disorders,
Pharmacogenomics J. 2 (2002) 217–235.
[18] A. Yamashita, S.K. Singh, T. Kawate, Y. Jin, E. Gouaux, Crystal structure of
a bacterial homologue of Na+/Cl− dependent neurotransmitter transporters,
Nature 437 (2005) 215–223.
[19] S.K. Singh, A. Yamashita, E. Gouaux, Antidepressant binding site in a
bacterial homologue of neurotransmitter transporters, Nature 448 (2007)
952–956.
[20] Z. Zhou, J. Zhen, N.K. Karpowich, R.M. Goetz, C.J. Law,M.E. Reith, D.N.
Wang, LeuT-Desipramine Structure Reveals How Antidepressants Block
Neurotransmitter Reuptake, Science (2007).
[21] B. Miroux, J.E. Walker, Over-production of proteins in Escherichia coli:
mutant hosts that allow synthesis of some membrane proteins and globular
proteins at high levels, J. Mol. Biol. 260 (1996) 289–298.
[22] N.C. Danbolt, Glutamate uptake, Prog. Neurobiol. 65 (2001) 1–105.[23] D. Yernool, O. Boudker, E. Folta-Stogniew, E. Gouaux, Trimeric subunit
stoichiometry of the glutamate transporters from Bacillus caldotenax and
Bacillus stearothermophilus, Biochemistry 42 (2003) 12981–12988.
[24] D.Yernool, O.Boudker,Y. Jin, E.Gouaux, Structure of a glutamate transporter
homologue from Pyrococcus horikoshii, Nature 431 (2004) 811–818.
[25] O. Boudker, R.M. Ryan, D. Yernool, K. Shimamoto, E. Gouaux, Coupling
substrate and ion binding to extracellular gate of a sodium-dependent
aspartate transporter, Nature 445 (2007) 387–393.
[26] M.E. Malo, L. Fliegel, Physiological role and regulation of the Na+/H+
exchanger, Can. J. Physiol. Pharmacol. 84 (2006) 1081–1095.
[27] L. Fliegel, C. Sardet, J. Pouyssegur, A. Barr, Identification of the protein and
cDNA of the cardiac Na+/H+ exchanger, FEBS Lett. 279 (1991) 25–29.
[28] X.H. Xiao, D.G. Allen, The role of endogenous angiotensin II in ischaemia,
reperfusion and preconditioning of the isolated rat heart, Pflugers Arch. 445
(2003) 643–650.
[29] H.E. Cingolani, I.L. Ennis, Sodium–hydrogen exchanger, cardiac over-
load, and myocardial hypertrophy, Circulation 115 (9) (2007) 1090–1100.
[30] C. Hunte, E. Screpanti, M. Venturi, A. Rimon, E. Padan, H. Michel,
Structure of a Na+/H+ antiporter and insights into mechanism of action and
regulation by pH, Nature 435 (2005) 1197–1202.
[31] D.D. Shultis, M.D. Purdy, C.N. Banchs, M.C. Wiener, Outer membrane
active transport: structure of the BtuB:TonB complex, Science 312 (2006)
1396–1399.
[32] P.D. Pawelek, N. Croteau, C. Ng-Thow-Hing, C.M. Khursigara, N.
Moiseeva, M. Allaire, J.W. Coulton, Structure of TonB in complex with
FhuA, E. coli outer membrane receptor, Science 312 (2006) 1399–1402.
[33] W. Kühlbrandt, Three-dimensional crystallization of membrane proteins.
Quart. Rev. Biophys. 21 (1988) 429–477.
[34] C. Toyoshima, M. Nakasako, H. Nomura, H. Ogawa, Crystal structure of
the calcium pump of sarcoplasmic reticulum at 2.6 A resolution, Nature
405 (2000) 647–655.
[35] M.J. Lemieux, R.A. Reithmeier, D.N. Wang, Importance of detergent and
phospholipid in the crystallization of the human erythrocyte anion-
exchanger membrane domain, J. Struct. Biol. 137 (2002) 322–332.
[36] M.J. Lemieux, Eukaryotic major facilitator superfamily transporter
modeling based on the prokaryotic GlpT crystal structure (Review), Mol.
Membr. Biol. 24 (2007) 333–341.
[37] S.B. Long, E.B. Campbell, R. Mackinnon, Crystal structure of a mammalian
voltage-dependent Shaker family K+ channel, Science 309 (2005) 897–903.
[38] P.L. Sorgen, Y. Hu, L. Guan, H.R. Kaback, M.E. Girvin, An approach to
membrane protein structure without crystals, Proc. Natl. Acad. Sci. U. S. A.
99 (2002) 14037–14040.
[39] J. Zhuang, G.G. Prive, G.E. Werner, P. Ringler, H.R. Kaback, A. Engel,
Two-dimensional crystallization of Escherichia coli lactose permease,
J. Struct. Biol. 125 (1999) 63–75.
[40] G. Chang, R.H. Spencer, A.T. Lee, M.T. Barclay, D.C. Rees, Structure of
the MscL homolog from Mycobacterium tuberculosis: a gated mechan-
osensitive ion channel, Science 282 (1998) 2220–2226.
